文献速递肝病

活化的肝星状细胞和门管区成纤维细胞参与MDR2敲除小鼠胆汁淤积性肝纤维化

Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice.
PubMed 文献 · J Hepatol · 2019-05-07

Mdr2-/-小鼠是模拟原发性硬化性胆管炎的遗传模型。研究显示活化的门管区成纤维细胞和肝星状细胞是胶原生成的主要来源,骨髓来源纤维细胞贡献极小;在12-16周龄Mdr2-/-小鼠中给予NOX1/4抑制剂可抑制肌成纤维细胞活化并减轻胆汁淤积性肝纤维化。

要点

  • Mdr2-/-小鼠中活化的门管区成纤维细胞占胶原GFP阳性肌成纤维细胞的26%、51%和54%(4、8、16周龄)。
  • 剩余胶原GFP阳性肌成纤维细胞由活化的肝星状细胞构成,骨髓来源纤维细胞贡献极小。
  • 12周龄起给予NOX抑制剂可抑制肌成纤维细胞活化并减轻胆汁淤积性肝纤维化。

核心结论

  • 活化的门管区成纤维细胞和活化的肝星状细胞参与Mdr2-/-小鼠胆汁淤积性肝纤维化,并可作为抗纤维化治疗的靶点。

研究设计与样本

  • 研究采用表达胶原-GFP报告基因的Mdr2-/-小鼠,在不同年龄分析肝脏非实质细胞,并根据胶原-GFP和维生素A分选细胞。
  • 对12-16周龄Mdr2-/-小鼠给予NADPH氧化酶1/4抑制剂,评估靶向氧化应激治疗胆汁淤积性损伤的效果。

主要发现

  • Thy1+活化的门管区成纤维细胞在4、8、16周龄Mdr2-/-小鼠中分别占胶原-GFP阳性肌成纤维细胞的26%、51%和54%。
  • 剩余胶原-GFP阳性肌成纤维细胞由活化的肝星状细胞组成,骨髓来源纤维细胞对肝纤维化贡献极小。
  • Mdr2-/-小鼠胆汁淤积性肝纤维化的发生与4周龄时Gr1+髓系细胞的早期募集和促炎细胞因子上调相关。
  • 对12周龄Mdr2-/-小鼠给予NOX抑制剂可抑制肌成纤维细胞活化并减轻胆汁淤积性纤维化的发生。

临床怎么用

  • 作者认为活化的门管区成纤维细胞和肝星状细胞可作为胆汁淤积性损伤抗纤维化治疗的靶点。
  • 作者指出靶向NADPH氧化酶可能是治疗胆汁淤积性肝纤维化的有效策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Chronic liver injury often results in the activation of hepatic myofibroblasts and the development of liver fibrosis. Hepatic myofibroblasts may originate from 3 major sources: hepatic stellate cells (HSCs), portal fibroblasts (PFs), and fibrocytes, with varying contributions depending on the etiology of liver injury. Here, we assessed the composition of hepatic myofibroblasts in multidrug resistance gene 2 knockout (Mdr2-/-) mice, a genetic model that resembles primary sclerosing cholangitis in patients. METHODS: Mdr2-/- mice expressing a collagen-GFP reporter were analyzed at different ages. Hepatic non-parenchymal cells isolated from collagen-GFP Mdr2-/- mice were sorted based on collagen-GFP and vitamin A. An NADPH oxidase (NOX) 1/4 inhibitor was administrated to Mdr2-/- mice aged 12-16 weeks old to assess the therapeutic approach of targeting oxidative stress in cholestatic injury. RESULTS: Thy1+ activated PFs accounted for 26%, 51%, and 54% of collagen-GFP+ myofibroblasts in Mdr2-/- mice at 4, 8, and 16 weeks of age, respectively. The remaining collagen-GFP+ myofibroblasts were composed of activated HSCs, suggesting that PFs and HSCs are both activated in Mdr2-/- mice. Bone-marrow-derived fibrocytes minimally contributed to liver fibrosis in Mdr2-/- mice. The development of cholestatic liver fibrosis in Mdr2-/- mice was associated with early recruitment of Gr1+ myeloid cells and upregulation of pro-inflammatory cytokines (4 weeks). Administration of a NOX inhibitor to 12-week-old Mdr2-/- mice suppressed the activation of myofibroblasts and attenuated the development of cholestatic fibrosis. CONCLUSIONS: Activated PFs and activated HSCs contribute to cholestatic fibrosis in Mdr2-/- mice, and serve as targets for antifibrotic therapy. LAY SUMMARY: Activated portal fibroblasts and hepatic stellate cells, but not fibrocytes, contributed to the production of the fibrous scar in livers of Mdr2-/- mice, and these cells can serve as targets for antifibrotic therapy in cholestatic injury. Therapeutic inhibition of the enzyme NADPH oxidase (NOX) in Mdr2-/- mice reversed cholestatic fibrosis, suggesting that targeting NOXs may be an effective strategy for the treatment of cholestatic fibrosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Nishio T, Hu R, Koyama Y, et al. Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. J Hepatol. 2019. PMID: 31071368. doi:10.1016/j.jhep.2019.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。